Ikhwan Rinaldi1, Melva Louisa2, Fikri Ichsan Wiguna3, Elizabeth Budiani3, Jeffrey Christian Mahardhika3, Khairul Hukmi3. 1. Department of Internal Medicine Division of Hematology and Medical Oncology, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia. 2. Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Indonesia. 3. Faculty of Medicine, Universitas Indonesia, Indonesia.
Abstract
BACKGROUND: Fms-like tyrosine kinase-3, internal tandem duplication (FLT3-ITD) mutation, is a known predictor for worse outcome in patients with acute myeloblastic leukemia (AML). However, the prognostic significance of FLT3-ITD mutation in adult, non-transplant patients is still unclear therefore we conducted a systematic review and meta-analysis to explain this issue. The main outcome was overall survival (OS), while additional outcomes included event-free survival (EFS). METHODS: Seven Databases (ScienceDirect, Scopus, PubMed, Cochrane, SpringerLink, ProQuest, and EBSCOhost) were searched up to August 2020. Studies investigating the prognostic value of AML in adults with FLT3-ITD mutational status were selected. Studies which patients had received transplantation, diagnosed with acute promyelocytic leukemia (APL) or secondary AML were excluded. The selected studies were divided into subgroups based on their cytogenetic profile. Summary hazard ratios (HR) and 95% confidence intervals (CI) were calculated using fixed-effects models. Heterogeneity tests were conducted and presented in I2 value. Forest plot was presented to facilitate understanding of the results. Publication bias was analyzed by Funnel Plot test. RESULTS: A total of ten studies describing research conducted from 1999 to 2020, met the inclusion criteria for this study. Nine studies reported OS and four studies reported EFS in HR. The highest HR for OS is 6.33 (95% CI, 2.61-15.33; p < 0.001), for EFS is 3.58 (95% CI, 1.59 - 8.05); p = 0.002)., while the lowest for OS is 1.33 (95% CI, 0.88-2.01; P = 0.174) and for EFS is 1.29 (95% CI, 0.75-2.23; p = 0.34). Nine studies were included in meta-analysis with HR for OS 1.91 (95% CI, 1.59-2.30, p < 0.00001), whereas 4 studies were included in meta-analysis for EFS with HR 1.64 (95% CI, 1.25-2.14; p = 0.0003). CONCLUSION: FLT3-ITD mutation is associated with worse prognosis in adult, non-transplant patients with AML, both for OS and EFS.
BACKGROUND:Fms-like tyrosine kinase-3, internal tandem duplication (FLT3-ITD) mutation, is a known predictor for worse outcome in patients with acute myeloblastic leukemia (AML). However, the prognostic significance of FLT3-ITD mutation in adult, non-transplant patients is still unclear therefore we conducted a systematic review and meta-analysis to explain this issue. The main outcome was overall survival (OS), while additional outcomes included event-free survival (EFS). METHODS: Seven Databases (ScienceDirect, Scopus, PubMed, Cochrane, SpringerLink, ProQuest, and EBSCOhost) were searched up to August 2020. Studies investigating the prognostic value of AML in adults with FLT3-ITD mutational status were selected. Studies which patients had received transplantation, diagnosed with acute promyelocytic leukemia (APL) or secondary AML were excluded. The selected studies were divided into subgroups based on their cytogenetic profile. Summary hazard ratios (HR) and 95% confidence intervals (CI) were calculated using fixed-effects models. Heterogeneity tests were conducted and presented in I2 value. Forest plot was presented to facilitate understanding of the results. Publication bias was analyzed by Funnel Plot test. RESULTS: A total of ten studies describing research conducted from 1999 to 2020, met the inclusion criteria for this study. Nine studies reported OS and four studies reported EFS in HR. The highest HR for OS is 6.33 (95% CI, 2.61-15.33; p < 0.001), for EFS is 3.58 (95% CI, 1.59 - 8.05); p = 0.002)., while the lowest for OS is 1.33 (95% CI, 0.88-2.01; P = 0.174) and for EFS is 1.29 (95% CI, 0.75-2.23; p = 0.34). Nine studies were included in meta-analysis with HR for OS 1.91 (95% CI, 1.59-2.30, p < 0.00001), whereas 4 studies were included in meta-analysis for EFS with HR 1.64 (95% CI, 1.25-2.14; p = 0.0003). CONCLUSION:FLT3-ITD mutation is associated with worse prognosis in adult, non-transplant patients with AML, both for OS and EFS.
Authors: V Ponziani; G Gianfaldoni; F Mannelli; F Leoni; S Ciolli; P Guglielmelli; E Antonioli; G Longo; A Bosi; A M Vannucchi Journal: Leukemia Date: 2006-08-31 Impact factor: 11.528
Authors: David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett Journal: Blood Date: 2010-04-12 Impact factor: 22.113
Authors: Victoria V Prassek; Maja Rothenberg-Thurley; Maria C Sauerland; Tobias Herold; Hanna Janke; Bianka Ksienzyk; Nikola P Konstandin; Dennis Goerlich; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Jan Braess; Stephanie Schneider; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Klaus H Metzeler Journal: Haematologica Date: 2018-06-14 Impact factor: 9.941
Authors: Noorwati Sutandyo; Resti Mulyasari; Agus Kosasih; Ikhwan Rinaldi; Melva Louisa; Andi Putra Kevinsyah; Kevin Winston Journal: Asian Pac J Cancer Prev Date: 2022-04-01